Sitravatinib
- Generic Name
- Sitravatinib
- Drug Type
- Small Molecule
- Chemical Formula
- C33H29F2N5O4S
- CAS Number
- 1123837-84-2
- Unique Ingredient Identifier
- CWG62Q1VTB
- Background
Sitravatinib is under investigation in clinical trial NCT03680521 (Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma).
Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy Adults
- First Posted Date
- 2020-07-15
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 26
- Registration Number
- NCT04472650
- Locations
- 🇦🇺
Linear Clinical Research, Nedlands, Western Australia, Australia
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 430
- Registration Number
- NCT04164199
- Locations
- 🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇺🇸Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
🇺🇸Memorial Sloan Kettering Cancer Center Mskcc, New York, New York, United States
Sitravatinib in Metastatic Breast Cancer
- Conditions
- Triple Negative Breast CancerBreast Cancer Stage IVBreast NeoplasmsBreast Cancer Metastatic
- Interventions
- First Posted Date
- 2019-10-11
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Xiang Zhang
- Target Recruit Count
- 3
- Registration Number
- NCT04123704
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
- Conditions
- Carcinoma, HepatocellularGastric/Gastroesophageal Junction Cancer
- Interventions
- First Posted Date
- 2019-05-08
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 111
- Registration Number
- NCT03941873
- Locations
- 🇨🇳
Sun Yat Sen Memorial Hospital, Sun Yat Sen University (North), Guangzhou, Guangdong, China
🇨🇳Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
- Conditions
- Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2019-04-08
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 577
- Registration Number
- NCT03906071
- Locations
- 🇺🇸
Local Institution - 005-164, Birmingham, Alabama, United States
🇺🇸Clearview Cancer Institute - Huntsville, Huntsville, Alabama, United States
🇺🇸Palo Verde Cancer Specialists - Glendale, Glendale, Arizona, United States
Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma
- Conditions
- Clear Cell Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2018-09-21
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT03680521
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors
- First Posted Date
- 2018-09-11
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 216
- Registration Number
- NCT03666143
- Locations
- 🇦🇺
Icon Cancer Foundation, South Brisbane, Queensland, Australia
🇦🇺Austin Health, Heidelberg, Victoria, Australia
🇦🇺Linear Clinical Research, Nedlands, Western Australia, Australia
A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
- Conditions
- Urothelial CarcinomaUrothelial Carcinoma BladderUrothelial Carcinoma of the Renal Pelvis and UreterUrothelial Carcinoma UreterUrothelial Carcinoma Urethra
- Interventions
- First Posted Date
- 2018-07-30
- Last Posted Date
- 2023-08-24
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 260
- Registration Number
- NCT03606174
- Locations
- 🇺🇸
University of California Irvine, Irvine, California, United States
🇺🇸The University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study
- Conditions
- Squamous Cell Carcinoma, Head And NeckSquamous Cell Carcinoma MouthSquamous Cell Carcinoma of the Oral Cavity
- Interventions
- Biological: Nivolumab
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 10
- Registration Number
- NCT03575598
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer
- Conditions
- Clear Cell Renal Cell CarcinomaStage IV Renal Cell Cancer AJCC v7Metastatic Kidney CarcinomaStage III Renal Cell Cancer AJCC v7
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2017-01-10
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 42
- Registration Number
- NCT03015740
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.